var data={"title":"Fludarabine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fludarabine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6205?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">see &quot;Fludarabine: Drug information&quot;</a> and <a href=\"topic.htm?path=fludarabine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fludarabine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708775\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fludarabine can severely suppress bone marrow function.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Autoimmune effects:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Instances of life-threatening and sometimes fatal autoimmune phenomena, such as hemolytic anemia, autoimmune thrombocytopenia/thrombocytopenic purpura, Evans syndrome, and acquired hemophilia, have been reported to occur after 1 or more cycles of treatment with fludarabine. Patients undergoing treatment with fludarabine should be evaluated and closely monitored for hemolysis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neurotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">When used at high doses in dose-ranging studies in patients with acute leukemia, fludarabine was associated with severe neurologic effects, including blindness, coma, and death. This severe CNS toxicity occurred in 36% of patients treated with dosages approximately 4 times greater (96 mg/m<sup>2</sup>/day for 5 to 7 days) than the recommended dosage. Similar severe CNS toxicity, including agitation, coma, confusion, and seizures, has been reported (0.2% or less) in patients treated at doses in the range of the dose recommended for chronic lymphocytic leukemia.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Combination with pentostatin:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In a clinical investigation using fludarabine in combination with pentostatin (deoxycoformycin) for the treatment of refractory chronic lymphocytic leukemia, there was an unacceptably high incidence of fatal pulmonary toxicity. Therefore, the use of fludarabine in combination with pentostatin is not recommended.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fludarabine injection should be administered under the supervision of a qualified health care provider experienced in the use of antineoplastic therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171868\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Fludara [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171869\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fludara;</li>\n      <li>Fludarabine Phosphate for Injection;</li>\n      <li>Fludarabine Phosphate for Injection, USP;</li>\n      <li>Fludarabine Phosphate Injection, PPC STD.</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047440\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite (Purine Analog)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite (Purine Antagonist)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047432\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">see &quot;Fludarabine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: Refer to individual protocols; details concerning dosing in combination regimens should also be consulted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute lymphocytic leukemia (ALL) or AML, relapsed:</b> Limited data available: Children and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: 10.5 mg/m<sup>2</sup> bolus followed by 30.5 mg/m<sup>2</sup>/<b>day</b> for 48 hours in combination with cytarabine (Avramis 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent IV dosing: 25 mg/m<sup>2</sup> once daily for 5 days in combination with cytarabine and daunorubicin was used for ALL (Parker 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Stem cell transplant (allogeneic) conditioning regimen, reduced-intensity (hematologic malignancy):</b> Limited data available: Children and Adolescents: IV: 30 mg/m<sup>2</sup> once daily for 6 doses beginning 7 to 10 days prior to transplant (in combination with busulfan and thymoglobulin (Pulsipher 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Stem cell transplant (allogeneic) conditioning regimen, reduced-toxicity (myeloid malignancies and non-malignant diseases [eg, sickle cell cisease]):</b> Limited data available: Children and Adolescents: IV: 30 mg/m<sup>2</sup> once daily for 6 doses days -8 to -3 (in combination with busulfan and alemtuzumab) (Bhatia 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: Refer to individual protocols; details concerning dosing in combination regimens should also be consulted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic lymphocytic leukemia (CLL):</b> IV: 25 mg/m<sup>2</sup>/<b>day</b> for 5 days every 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: The following guidelines have been used by some clinicians (Aronoff 2007): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 80% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Administer 25% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous ambulatory peritoneal dialysis (CAPD): Not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): Administer 80% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer labeling: CLL: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 50 to 79 mL/minute: Decrease dose to 20 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 49 mL/minute: Decrease dose to 15 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following guidelines have been used by some clinicians (Aronoff 2007): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 50 mL/minute: Administer 75% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Administer 50% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Administer after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous ambulatory peritoneal dialysis (CAPD): Administer 50% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): Administer 75% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic or nonhematologic toxicity (other than neurotoxicity): Consider treatment delay or dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemolysis: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neurotoxicity: Consider treatment delay or discontinuation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171848\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as phosphate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as phosphate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as phosphate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fludara: 50 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as phosphate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171833\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047444\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Consult specific protocols.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent IV infusion: Infuse over 30 minutes; a shorter infusion has been used in some protocols (Avramis 1998)  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion with loading dose (bolus): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: Administer over 15 minutes (Avramis 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion:  Administer at a constant rate of 10 mL/hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132595\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration. In regions where an oral dosage form is available, NIOSH recommends single gloving for administration of intact tablets/capsules (NIOSH 2016).   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171862\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Store intact vials under refrigeration or at room temperature, as specified according to each manufacturer's labeling. Protect from light. Reconstituted solution or vials of the solution for injection that have been punctured (in use) should be used within 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet [Canadian product]: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); should be kept within packaging until use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047443\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of B-cell chronic lymphocytic leukemia (CLL) unresponsive to previous therapy with an alkylating agent-containing regimen (FDA approved in ages &ge;18 years); has also been used in the treatment of relapsed acute lymphocytic leukemia (ALL) or acute myeloid leukemia (AML), reduced-intensity conditioning regimens prior to allogeneic hematopoietic stem cell transplantation, non-Hodgkin lymphomas (NHL), and AML in either refractory or in poor risk patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171916\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fludarabine may be confused with cladribine, floxuridine, flucytosine, Flumadine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fludara may be confused with FUDR</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3339964\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Aneurysm, angina pectoris, cardiac arrhythmia, cardiac failure, cerebrovascular accident, deep vein thrombosis, edema, myocardial infarction, phlebitis, supraventricular tachycardia, transient ischemic attacks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Cerebellar syndrome, chills, depression, difficulty thinking, fatigue, headache, malaise, neurological signs and symptoms (characterized by cortical blindness, coma, and paralysis; symptom onset may be delayed for 3 to 4 weeks), pain, paresthesia, sleep disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, diaphoresis, pruritus, seborrhea, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration, hyperglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, cholelithiasis, constipation, diarrhea, dysphagia, esophagitis, gastrointestinal hemorrhage, mucositis, nausea and vomiting, stomatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysuria, hematuria, proteinuria, urinary hesitancy, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, bone marrow depression (nadir: 10 to 14 days; recovery: 5 to 7 weeks; dose-limiting toxicity), hemorrhage, neutropenia (nadir: ~13 days), thrombocytopenia (nadir: ~16 days), tumor lysis syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, hepatic failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia, osteoporosis, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Hearing loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal failure, renal function test abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, cough, dyspnea, epistaxis, hemoptysis, hypersensitivity pneumonitis, hypoxia, pharyngitis, pneumonia, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acquired blood coagulation disorder, acute myelocytic leukemia (usually associated with prior or concurrent treatment with other anticancer agents), adult respiratory distress syndrome, autoimmune hemolytic anemia, autoimmune thrombocytopenia, blindness, bone marrow aplasia (trilineage), bone marrow depression (trilineage), cerebral hemorrhage, coma, Epstein-Barr-associated lymphoproliferative disorder, erythema multiforme, Evan&rsquo;s syndrome, hemorrhagic cystitis, herpes zoster (reactivation), hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, immune thrombocytopenia (autoimmune), interstitial pneumonitis, malignant neoplasm of skin (new-onset or exacerbation), metabolic acidosis, myelodysplastic syndrome (usually associated with prior or concurrent treatment with other anticancer agents), myelofibrosis, opportunistic infection, optic neuritis, optic neuropathy, pancytopenia, pemphigus, pericardial effusion, peripheral neuropathy, pneumonitis, progressive multifocal leukoencephalopathy (PML), pulmonary fibrosis, pulmonary hemorrhage, reactivation of latent Epstein-Barr virus, respiratory distress, respiratory failure, seizure, Stevens-Johnson syndrome, toxic epidermal necrolysis, urate crystalluria, wrist-drop</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171854\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Hypersensitivity to fludarabine or any component of the formulation; severe renal impairment (CrCl &lt;30 mL/minute); decompensated hemolytic anemia; concurrent use with pentostatin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171837\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune effects: <b>[US Boxed Warning]: Life-threatening (and sometimes fatal) autoimmune effects, including hemolytic anemia, autoimmune thrombocytopenia/thrombocytopenic purpura (ITP), Evans syndrome, and acquired hemophilia have occurred; evaluate and monitor closely for hemolysis.</b> This has occurred in patients with and without a history of autoimmune hemolytic anemia or a positive Coombs test, and who may or may not be in remission from their disease. Corticosteroids may or may not effectively control the hemolytic episodes. Discontinue fludarabine if hemolysis occurs. The hemolytic effects recurred in most patients when rechallenged with fludarabine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Severe bone marrow suppression (anemia, thrombocytopenia, and neutropenia) may occur;</b> may be cumulative. The median time to nadir was 13 days (range: 3 to 25 days) for granulocytes and 16 days (range: 2 to 32 days) for platelets. Severe myelosuppression (trilineage bone marrow hypoplasia/aplasia) has been reported (rare) with a duration of significant cytopenias ranging from 2 months to 1 year. First-line combination therapy is associated with prolonged cytopenias, with anemia lasting up to 7 months, neutropenia up to 9 months, and thrombocytopenia up to 10 months; increased age is predictive for prolonged cytopenias (Gill 2010). Monitor patients with bone marrow impairment closely for excess toxicity; may require dosage reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Serious and sometimes fatal infections, including opportunistic infections and reactivations of latent viral infections such as VZV (herpes zoster) and Epstein-Barr virus have been reported with fludarabine. Prophylactic anti-infectives should be considered for patients with an increased risk for developing opportunistic infections. Use with caution in patients with documented infection, fever, immunodeficiency, or with a history of opportunistic infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity:<b> [US Boxed Warning]: Higher than recommended doses (up to 96 mg/m<sup>2</sup>/day for 5 to 7 days) are associated with severe neurologic toxicity (delayed blindness, coma, death); similar neurotoxicity (agitation, coma, confusion, seizure) has been reported (rare) with standard CLL doses (25 mg/m<sup>2</sup>/day for 5 days).</b> Symptoms of neurotoxicity due to high doses appeared from 21 to 60 days following the last fludarabine dose, although neurotoxicity has been reported as early as 7 days and up to 225 days. Although administration of up to 15 courses of treatment have been used, the possible neurotoxic effects of chronic administration are unknown. Fatigue, weakness, visual disturbances, confusion, and seizures may occur; caution patients about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy (PML) (usually fatal) due to JC virus has been reported; most cases were in patients who had received prior and/or other concurrent chemotherapy. Onset may be a few weeks or may be delayed up to 1 year. Evaluate any neurological change promptly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reproductive effects: Fludarabine may damage testicular tissue and spermatozoa.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transfusion-associated graft-versus-host disease: Graft-versus-host disease (GVHD) has been observed following transfusion of non-irradiated blood in patients treated with fludarabine; fatal outcome has been observed. Patients receiving fludarabine should only receive irradiated blood products due to the potential for transfusion-related GVHD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: May cause tumor lysis syndrome; risk is increased in patients with large tumor burden prior to treatment. Hydration and prophylactic antihyperuricemic therapy should be considered in patients at risk for tumor lysis syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; clearance of the primary metabolite 2-fluoro-ara-A is decreased in patients with renal impairment. Dosage reductions are recommended (monitor closely for excessive toxicity) in patients with creatinine clearance between 30 and 79 mL/minute; use is not recommended if CrCl &lt;30 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pentostatin: <b>[US Boxed Warning]: The use of fludarabine in combination with pentostatin (deoxycoformycin) for the treatment of refractory chronic lymphocytic leukemia has resulted in an unacceptably high incidence of fatal pulmonary toxicity. The use of fludarabine in combination with pentostatin is not recommended.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Monitor closely for excessive toxicity; may require reduced doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician:<b> [US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Live vaccines: Avoid vaccination with live vaccines during and after fludarabine treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299343\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171842\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13305&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May diminish the myelosuppressive effect of Fludarabine. Imatinib may decrease the serum concentration of Fludarabine. More specifically, imatinib may decrease the formation of fludarabine active metabolite F-ara-ATP Management: Due to the risk for impaired fludarabine response, consider discontinuing imatinib therapy at least 5 days prior to initiating fludarabine conditioning therapy in CML patients undergoing HSCT.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentostatin: Fludarabine may enhance the adverse/toxic effect of Pentostatin. Pentostatin may enhance the adverse/toxic effect of Fludarabine. Pulmonary toxicity is of specific concern. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171844\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171856\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Based on the mechanism of action, fludarabine may cause fetal harm if administered during pregnancy. Effective contraception should be used to avoid pregnancy during and after treatment for women and men with female partners of reproductive potential.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047439\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, platelet count, hemoglobin, AST, ALT, creatinine, serum electrolytes, albumin, uric acid, and examination for visual changes; monitor for signs of infection and neurotoxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171836\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fludarabine inhibits DNA synthesis by inhibition of DNA polymerase and ribonucleotide reductase; also inhibits DNA primase and DNA ligase I</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171853\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: 11 to 96 L/m<sup>2</sup> (Johnson 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 2-fluoro-ara-A: ~19% to 29%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: IV: Fludarabine phosphate is rapidly dephosphorylated in the plasma to 2-fluoro-ara-A (active metabolite), which subsequently enters tumor cells and is phosphorylated by deoxycytidine kinase to the active triphosphate derivative (2-fluoro-ara-ATP)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: 2-fluoro-ara-A: 50% to 65%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 2-fluoro-ara-A: Adults: ~20 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Oral: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (primarily) (Johnson 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323155\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Fludarabine Phosphate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $132.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171857\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Beneflur (ES, MX);</li>\n      <li>Flucozol (EC);</li>\n      <li>Fludabin (UA);</li>\n      <li>Fludabine (LK);</li>\n      <li>Fludacel (PE);</li>\n      <li>Fludalym (VN);</li>\n      <li>Fludamin (BD);</li>\n      <li>Fludara (AT, AU, BE, BG, BH, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PH, PL, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, UY, VE, VN, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007, 99, 172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avramis VI, Champagne J, Sato J, et al, &ldquo;Pharmacology of Fludarabine Phosphate After a Phase I/II Trial by a Loading Bolus and Continuous Infusion in Pediatric Patients,&rdquo; <i>Cancer Res</i>, 1990, 50(22):7226-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/1699658/pubmed\" target=\"_blank\" id=\"1699658\">1699658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatia M, Jin Z, Baker C, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from siblingdonors in children with sickle cell disease. <i>Bone Marrow Transplant</i>. 2014;49(7):913-920.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/24797180/pubmed\" target=\"_blank\" id=\"24797180\">24797180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gill S, Carney D, Ritchie D, et al, &quot;The Frequency, Manifestations, and Duration of Prolonged Cytopenias After First-Line Fludarabine Combination Chemotherapy,&quot; <i>Ann Oncol</i>, 2010, 21(2):331-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/19625344/pubmed\" target=\"_blank\" id=\"19625344\">19625344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lange BJ, Smith FO, Feusner J, et al, &quot;Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for Untreated Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group,&quot; <i>Blood</i>, 2008, 111(3):1044-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/18000167/pubmed\" target=\"_blank\" id=\"18000167\">18000167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker C, Waters R, Leighton C, et al, &quot;Effect of Mitoxantrone on Outcome of Children With First Relapse of Acute Lymphoblastic Leukaemia (ALL R3): An Open-Label Randomised Trial,&quot; <i>Lancet</i>, 2010, 376(9757):2009-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/21131038/pubmed\" target=\"_blank\" id=\"21131038\">21131038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pulsipher MA, Boucher KM, Wall D, et al, &quot;Reduced-Intensity Allogeneic Transplantation in Pediatric Patients Ineligible for Myeloablative Therapy: Results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313,&quot; <i>Blood</i>, 2009, 114(7):1429-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/19528536/pubmed\" target=\"_blank\" id=\"19528536\">19528536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in the healthcare settings 2014. Available at <a href=\"https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf\" target=\"_blank\">https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf</a></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13305 Version 154.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708775\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F171868\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F171869\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047440\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047432\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F171848\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F171833\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047444\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132595\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F171862\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047443\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F171916\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3339964\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F171854\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F171837\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299343\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F171842\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F171844\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F171856\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047439\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F171836\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F171853\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323155\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F171857\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13305|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">Fludarabine: Drug information</a></li><li><a href=\"topic.htm?path=fludarabine-patient-drug-information\" class=\"drug drug_patient\">Fludarabine: Patient drug information</a></li></ul></div></div>","javascript":null}